Text-only word count: 3368 Methods: 430 elite female athletes completed a questionnaire to assess; the period prevalence of HC use, the reasons for initiation and discontinuation of HCs and the side effects experienced by HC and non-HC users. Descriptive statistics, between-group comparisons and associations between categorical variables were calculated. Results: 49.5% of athletes were currently using HCs and 69.8% had used HCs at some point. Combined oral contraceptives were most commonly used (68.1%), with 30.0% using progestin-only contraceptives (implant = 13.1%; injection = 3.7%; intrauterine system = 2.8%). Perceived negative side effects were more common with progestin-only HC use (39.1%) compared to combined HC use (17.8%; P = 0.001) and were most prevalent in implant users (53.6%; P = 0.004). HC users reported 
Introduction
Alterations to the female reproductive-axis influence health and athletic performance. [1] [2] [3] Between menarche and the menopause, non-hormonal contraceptive users typically have a monthly menstrual cycle, with a cyclical rise and fall in sex hormone concentrations. 4 Primary dysmenorrhea, which is characterised by painful menstruation, nausea, headaches, fatigue and diarrhoea, 5 is experienced by 60-91% of non-hormonal contraceptive users 6 and may affect athletic performance. 7 In a recent study, 51% of athletes (n = 90) perceived that the menstrual cycle affected their training and performance. 8 Despite this, little is known about menstrual cycle related side effects, when they occur and how training and performance may be influenced.
Hormonal contraceptives (HCs) are exogenous steroid hormones that inhibit ovulation and result in consistently low endogenous sex hormone concentrations, which can be used to treat dysmenorrhea. 9, 10 There are different delivery methods for HCs including the oral contraceptive (OC), implant, injection, transdermal patch, vaginal ring and intra-uterine system (IUS). In the UK, a hormone releasing coil is typically referred to as an IUS, whereas a copperbased, non-hormone releasing coil is referred to as an intra-uterine device (IUD) and, as such,
would not be considered a type of HC. Hormonal contraceptives can also be classified by type; combined, with an oestrogenic and progestin component, or progestin-only. The type and concentration of oestrogen and progestin varies between different preparations of contraceptive, and may influence the physiological response.
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In a large-scale epidemiological study of >194,000 women, Cea-Soirano et al. 14 reported that 30% of 16-49 year olds in the UK used HCs: combined OCs (16.2%), progestinonly OCs (5.6%), IUSs (4.2%), injections (2.4%), implants (1.5%), transdermal contraceptive patches (0.1%), with 4.5% using non-hormonal copper-based coils (IUDs). The prevalence of HC use in athletes has been poorly defined by previous research. In elite Norwegian athletes, OC use was 40.2%, which was significantly higher than a control population (27%), 15 while 46% of Swedish football, volleyball and basketball athletes used OCs. 16 Other studies have reported low OC use in athletes (~14%), 17, 18 although this may be due to the inclusion of nonelite athletes, who may be more analogous to the general population. Previous research in elite athletes has only reported OC use and has not considered other delivery methods of HCs or detailed the preparations used by participants, which influence endogenous hormone concentrations and other physiological processes. [11] [12] [13] No study has identified the reasons why elite athletes initiate or discontinue HC use, or the perceived side effects.
Elite female athletes are required to train and compete whilst having to manage changes in sex hormone concentration and their subsequent side effects. The current lack of understanding of these side effects is a barrier to implementing strategies to support athletes and promote optimal health and performance. The aim of this study was to identify (1) the period prevalence of HC use, (2) the reasons for initiation and discontinuation of HCs and (3) the side effects experienced by HC users and non-users in an elite athletic population.
Materials and methods

Participants
Between 2015-2016, elite female athletes were recruited through National Governing
Bodies, coaching and support staff, or by approaching the athletes directly. Athletes had to be >18 y and competing at a national, international or professional (full-time and salaried) level.
A paper-based questionnaire was used in order to minimise the possibility that the questionnaire could be completed by the non-targeted population. 19 A total of 476 athletes completed the questionnaire, with 430 responses included in the final analysis (Figure 1 ).
Athletes were recruited from 24 sports with 361 competing at an international/professional 
Data analysis
Data were analysed using Microsoft Excel and IBM SPSS (v. 23.0). To prevent duplicate data, the database was searched for non-unique date of births and identical values were visually checked to assess whether the respondents were different. Athletes were categorised by competitive level (national or international/professional) to conduct a stratified
analysis. For open-ended questions, a content analysis was conducted independently by two researchers (DM, KES) to categorise responses, whereby a frequency analysis was performed, which was checked for consistency. Differences between the researchers were resolved by discussion until a consensus was reached. Direct verbatim quotes were used to inform interpretation in some instances. Assumptions of normality were checked using the ShapiroWilk test and between group differences were examined using independent samples t-tests, Mann-Whitney U tests and Kruskal Wallis H tests. Pearson's chi-squared analyses were used to examine the relationships between categorical variables, with Fishers exact tests used where <80% of expected cell counts were >5. 20 Data are represented as mean ± 1SD, frequencies and percentages and statistical significance was set at p ≤ 0.05.
Results
Three hundred (69.8%) athletes reported using HCs at some point, with 49.5% of athletes currently using HCs and 50.5% not currently using any form of HC (Fig 1) . Hormonal contraceptive users had a lower age of menarche (p = 0.010) and length of time competing at current level (p = 0.048) compared to non-HC users (participant characteristics in Table 1 ).
Competitive level did not influence the prevalence of HC use (p > 0.05).
Menstrual cycle (non -hormonal contraceptive users)
Three athletes described themselves as amenorrheic, although the questionnaire did not specifically ask this question. Thirty-four athletes did not report their menstrual cycle length or and categorical frequencies are presented in Table 2 . Symptoms were experienced in the week prior to menstruation (25.0%), during days 1 and 2 of menstruation (81.6%) and between day 3 and the end of menstruation (28.9%). Nine athletes (4.1%) reported that they had to refrain from exercise at certain points of their menstrual cycle. Reasons included pain (n = 4), sickness (n = 2), or other reasons (n = 3), such as "Literally struggle to get out of bed so training is out of the question" or "at the beginning of the menstrual cycle I avoid to do tough session [sic]".
Four athletes reported that they didn't refrain from exercise, although they provided additional comments stating "No -but only because I can't", "but struggle with contact [rugby]", "but I get back cramps 1 week before when running" and "I don't avoid it but I do sometimes have to delay things until cramps calm down". One athlete stated that "If anything I have to increase it [exercise]. Helps to pass quicker by maybe a day and helps the pain".
Hormonal contraceptive use
Combined HCs comprised 68.5% of HC use, with 30.0% using progestin-only and 1.9%
using an unspecified type of OC. There was no difference in length of current HC use between combined (4.6 ± 3.7 y) and progestin-only HC users (3.9 ± 4.4 y; p = 0.193), or between different delivery methods (p = 0.649). Oral contraceptives were the most widely used (78.4%), followed by the implant (13.1%), injection (3.8%), IUS (2.8%) and vaginal ring (0.5%), with Table 3 . Negative side effects were significantly more common with progestin-only HCs (39.1%) compared to combined HCs (17.8%; p = 0.001) and were significantly more common in the implant (53.6%) compared to other delivery methods (p = 0.004; Table 4 ). Type and delivery method of HC did not affect the prevalence of reported positive effects (p > 0.05). HC users were significantly more likely to report positive effects of HCs than negative effects (p < 0.05).
International/professional athletes were significantly more likely to discuss HC use with their coach/team doctor (25%) compared to national level athletes (0%; p < 0.001).
Competitive level did not influence coach/team doctor involvement in the decision to initiate HC use (p = 0.070), although this did occur for 7.6% of international/professional athletes and no national level athletes. The coach/team doctor was involved in the decision to use HCs for 14 (6.6%) athletes, of which 12 used OCs and 2 used an implant. Ultra-low dose EO (20 µg)
OCs accounted for 25% of OC use in this group, in comparison to 2.7% of overall OC use, which was a significant effect (p = 0.010). Where the coach/team doctor was involved in the decision, athletes stated that they were prescribed these HCs for contrasting reasons including;
'Higher level of oestrogen", "Apparently lowest oestrogen", "Low hormones" and "In attempt to reduce monthly fluctuations in my performance and fatigue".
In total, 87 (40.1%) non-HC users had previously used some form of HC, with 64 (30.0%) current HC users previously using a different HC. There were 218 incidences of previous HC use, as some athletes had used 2 (n = 49), 3 (n = 13), 4 (n = 4) and 5 (n = 1) previous types of HC. Combined OCs accounted for 78.4% of previous use, with progestinonly OCs (7.8%), implant (7.8%), injection (6.0%) and IUS (1.8%) also used. The reasons provided for discontinuation of previous HCs are presented in Table 5 . Mean duration of previous HC use was 2.2 ± 2.3 y, with no difference between types (p = 0.360) or delivery methods (p = 0.733).
Discussion
This novel study has shown that there is an approximately even prevalence of HC use and non-HC use in elite female athletes. The majority of female athletes have used HCs at some point in their sporting career. These results highlight the importance of understanding the effects of the menstrual cycle and HC use in elite sportswomen. This is the first study to detail the symptoms experienced by athletes during the menstrual cycle and with HC use, and these data can be used to inform the decisions of athletes, practitioners and researchers.
The prevalence of HC use in elite athletes (49.5%) is higher than recent data for the general population of reproductive age in the UK (30.0%) 14 and USA (27.6%). 21 Sixty-nine percent of HCs used were combined OCs, which is also higher than in the general population where OCs account for 54.0% of HC use. 14 Schaumberg et al. 22 , showed that competitive (state, national and international) athletes rated sport competition and sport training as more important factors in menstrual manipulation with OCs, compared to sub-elite and recreationally active individuals. Furthermore, 43.5% of OC-using competitive athletes planned to manipulate with three cases involving the coach/team doctor in the decision to use this preparation, all of which were from different sports. Ultra-low dose OCs are associated with reduced headaches, nausea and breast tenderness compared to higher dose EO formulations 23 and can reduce the symptoms of dysmenorrhea 24 , so may have been prescribed to reduce these symptoms whilst maintaining the benefits of improved cycle control. These data are representative of a UK based population and further studies are required to expand this knowledge to other countries where the use of other formulations, such as extended cycle OCs, are more prevalent. 25 Combined HCs were better tolerated than progestin-only HCs; with 17.8% of combined-type users reporting negative side effects in comparison to 39.1% of progestin-only HC users. In particular, the implant had a significantly higher incidence of reported negative symptoms compared to other delivery methods of HCs ( reported increased weight which is lower than in the general population (34%). 26 Negative side effects associated with the menstrual cycle were reported by 77.4% of non-HC users, which is similar to the general population. 6 Exercise may reduce the occurrence and severity of dysmenorrhea, 27 although dysmenorrhea is still widespread in elite athletes.
The most commonly reported side effects were stomach cramps (47.5%), unspecified cramps (22.1%), back pain (17.1%) and headaches/migraines (9.7%). Despite having physically demanding lifestyles, only 4.2% of athletes stated that they refrained from exercise at certain points of their menstrual cycle, which is lower than the general population where dysmenorrhea
limits daily activities in 15-29% of women. 6 This discrepancy may be caused by internal and external pressures to perform, 28 meaning that athletes persevere with training whilst experiencing severe symptoms, evidenced by responses such as "No, but only because I can't [avoid exercise]". A recent study in HC users and non-users, showed 51.1% of athletes thought their menstrual cycle affected training and performance, 8 although the current data indicates that this rarely translates into athletes modifying training schedules to accommodate symptoms.
Twenty-four distinct, negative symptoms were reported by non-HC users (Table 2 ) and approximately half of the athletes reported menstrual cycle length variability with a relatively high mean variation of (9 ± 9 d) in these athletes. Although the current questionnaire did not ask specifically about amenorrhea, three athletes described themselves as amenorrheic, and we recommend that future studies explicitly ask this question in order to not under-represent the occurrence of amenorrhea in elite sport. Side effects were mostly experienced during the first two days of menstruation (81.6%), however also occurred in the week prior to menstruation non-users, (2) progestin-only contraceptive users and (3) differences between preparations of HC.
Practical Applications
Progestin-only contraceptives had a greater incidence of negative side effects and physicians may want to consider the increased prevalence of perceived negative side effects with these contraceptives. There is a large degree of individuality in the type and severity of symptoms experienced during the menstrual cycle and HC use, and in the reasons for initiating and discontinuing HC use. It is recommended that athletes and practitioners discuss side effects experienced with the menstrual cycle and HC use in order to suit the athletes' best interests.
This research also highlights that future research should include HC users and non-users in order to represent the female athlete population.
Conclusions
Approximately half of elite athletes use some type of HC, with combined OCs most commonly used, possibly due to the ability to predict and/or manipulate the timing, frequency and amount of menstrual bleeding. A large proportion of sportswomen use progestin-only contraceptives with a perceived benefit being that they induce amenorrhea. There is a larger inter-individual variability in response to HC use and the menstrual cycle which should be considered by athletes and practitioners. Table tennis Taekwondo Trampoline Swimming Cycling Orienteering n = 4 n = 4 n = 3 n = 3 n = 1 n = 1 n = 1 n = 1 
